Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' SEEBER S' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 171 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kasimir-Bauer, S; Mayer, S; Bojko, P; Borquez, D; Neumann, R; Seeber, S
      Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy

      CLINICAL CANCER RESEARCH
    2. Seeber, S
      EGFR in tumour growth: Biological role and clinical implications - Introduction

      EUROPEAN JOURNAL OF CANCER
    3. Stahl, C; Kubetzko, S; Kaps, I; Seeber, S; Engelhardt, H; Niederweis, M
      MspA provides the main hydrophilic pathway through the cell wall of Mycobacterium smegmatis

      MOLECULAR MICROBIOLOGY
    4. Jansen, M; Bardenheuer, W; Sorg, UR; Seeber, S; Flasshove, M; Moritz, T
      Protection of hematopoietic cells from O-6-alkylation damage by O-6-methylguanine DNA methyltransferase gene transfer: studies with different O-6-alkylating agents and retroviral backbones

      EUROPEAN JOURNAL OF HAEMATOLOGY
    5. Vanhoefer, U; Harstrick, A; Achterrath, W; Cao, SS; Seeber, S; Rustum, YM
      Irinotecan in the treatment of colorectal cancer: Clinical overview

      JOURNAL OF CLINICAL ONCOLOGY
    6. Kaps, I; Ehrt, S; Seeber, S; Schnappinger, D; Martin, C; Riley, LW; Niederweis, M
      Energy transfer between fluorescent proteins using a co-expression system in Mycobacterium smegmatis

      GENE
    7. Elmaagacli, AH; Runkel, K; Steckel, N; Opalka, B; Trenschel, R; Seeber, S; Schaefer, UW; Beelen, DW
      A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenousleukemia in first chronic phase

      BONE MARROW TRANSPLANTATION
    8. Bojko, P; Scheulen, ME; Hilger, R; Oberhoff, C; Schindler, AD; Seeber, S
      High-dose chemotherapy with peripheral blood stem cell transplantation forpatients with advanced ovarian cancer

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    9. Kasimir-Bauer, S; Oberhoff, C; Sliwinska, K; Neumann, R; Schindler, AE; Seeber, S
      Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use ?

      BREAST CANCER RESEARCH AND TREATMENT
    10. Kratzer, S; Mundigl, O; Dicker, F; Seeber, S
      Digital imaging microscopy of firefly luciferase activity to directly monitor differences in cell transduction efficiencies between AdCMVLuc and Ad5LucRGD vectors having different cell binding properties

      JOURNAL OF VIROLOGICAL METHODS
    11. Bacher, G; Nickel, B; Emig, P; Vanhoefer, U; Seeber, S; Shandra, A; Klenner, T; Beckers, T
      D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity

      CANCER RESEARCH
    12. Elmaagacli, AH; Freist, A; Hahn, M; Opalka, B; Seeber, S; Schaefer, UW; Beelen, DW
      Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method

      BRITISH JOURNAL OF HAEMATOLOGY
    13. Trarbach, T; Greifenberg, S; Bardenheuer, W; Elmaagacli, A; Hirche, H; Flasshove, M; Seeber, S; Moritz, T
      Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments

      CYTOTHERAPY
    14. Scheulen, ME; Hilger, RA; Oberhoff, C; Casper, J; F'reund, M; Josten, KM; Bornhauser, M; Ehninger, G; Berdel, WE; Baumgart, J; Harstrick, A; Bojko, P; Wolf, HH; Schindler, AE; Seeber, S
      Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies

      CLINICAL CANCER RESEARCH
    15. Muller, MR; Lennartz, K; Baack, B; Heim, MME; Seeber, S; Scheulen, ME
      Simultaneous measurement of cellular P-glycoprotein content and function by multiparametric flow-cytometry

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    16. Elmaagacli, AH; Beelen, DW; Opalka, B; Seeber, S; Schafer, UW
      The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage

      ANNALS OF HEMATOLOGY
    17. Ottinger, HD; Muller, C; Schmitz, N; Kubanek, B; Arnold, R; Ebell, W; Eberhard, HP; Ehninger, G; Fronz, U; Goldmann, S; Grosse-Wilde, H; Havers, W; Klingebiel, T; Kolb, HJ; Seeber, S; Schaefer, UW; Baldomero, H; Gratwohl, A
      Transplant activities in Germany in 1998 - a survey facilitated by the National Registry for Hemopoietic Stem Cell Transplantation

      ANNALS OF HEMATOLOGY
    18. Flasshove, M; Meusers, P; Schutte, J; Noppeney, R; Beelen, DW; Sohrab, S; Roggenbuck, U; Kemmeries, G; Brittinger, G; Seeber, S; Scheulen, ME
      Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia

      ANNALS OF HEMATOLOGY
    19. Dickopp, A; Esche, H; Swart, G; Seeber, S; Kirch, HC; Opalka, B
      Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cells

      CANCER GENE THERAPY
    20. Seeber, S
      A new era in oncology

      ONKOLOGIE
    21. Vanhoefer, U; Achterrath, W; Wilke, H; Seeber, S
      Preclinical evaluation of irinotecan

      ONKOLOGIE
    22. Hilger, RA; Jacek, G; Oberhoff, C; Kredtke, S; Baumgart, J; Seeber, S; Scheulen, ME
      Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    23. Stuschke, M; Stahl, M; Wilke, H; Walz, M; Oldenburg, A; Stuben, G; Seeber, S; Sack, H
      Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    24. Beelen, DW; Peceny, R; Elmaagacli, A; Ottinger, H; Kummer, G; Opalka, B; Seeber, S; Schaefer, UW
      Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34(+) cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study

      BONE MARROW TRANSPLANTATION
    25. Flasshove, M; Bardenheuer, W; Schneider, A; Hirsch, G; Bach, P; Bury, C; Moritz, T; Seeber, S; Opalka, B
      Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    26. Heim, MM; Eberhardt, W; Seeber, S; Muller, MR
      Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    27. Schroder, JK; Kasimir-Bauer, S; Seeber, S; Scheulen, ME
      In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    28. Schroder, JK; Kolkenbrock, S; Tins, J; Kasimir-Bauer, S; Seeber, S; Schutte, J
      Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia

      LEUKEMIA RESEARCH
    29. Vanhoefer, U; Schleucher, N; Klaassen, U; Seeber, S; Harstrick, A
      Ifosfamide-based drug combinations: Preclinical evaluation of drug interactions and translation into the clinic

      SEMINARS IN ONCOLOGY
    30. Seeber, S; Becker, K; Rau, T; Eschenhagen, T; Becker, CM; Herkert, M
      Transient expression of NMDA receptor subunit NR2B in the developing rat heart

      JOURNAL OF NEUROCHEMISTRY
    31. Werner, NS; Siprashvili, Z; Fong, LYY; Marquitan, G; Schroder, JK; Bardenheuer, W; Seeber, S; Huebner, K; Schutte, J; Opalka, B
      Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression

      CANCER RESEARCH
    32. Boyd, AC; Popp, F; Michaelis, U; Davidson, H; Davidson-Smith, H; Doherty, A; McLachlan, G; Porteous, DJ; Seeber, S
      Insertion of natural intron 6a-6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discrimination

      JOURNAL OF GENE MEDICINE
    33. Klaassen, U; Borquez, D; Lang, S; Oberhoff, C; Harstrick, A; Seeber, S; Benner, S
      Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer

      ONCOLOGY-NEW YORK
    34. Bojko, P; Nowak, N; Moritz, T; Flasshove, M; Harstrick, A; Seeber, S
      Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral bleed stem cells

      JOURNAL OF CLINICAL APHERESIS
    35. Bojko, P; Stellberg, W; Kudde, C; Scharifi, M; Herrmann, M; Mayer, S; Harstrick, A; Seeber, S
      Kinetic study of CD34+ cells during peripheral blood stem cell collections

      JOURNAL OF CLINICAL APHERESIS
    36. Stuschke, M; Eberhardt, W; Pottgen, C; Stamatis, G; Wilke, H; Stuben, G; Stoblen, F; Wilhelm, HH; Menker, H; Teschler, H; Muller, RD; Budach, V; Seeber, S; Sack, H
      Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigationsof late neuropsychologic effects

      JOURNAL OF CLINICAL ONCOLOGY
    37. Vanhoefer, U; Harstrick, A; Kohne, CH; Achterrath, W; Rustum, YM; Seeber, S; Wilke, H
      Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer

      JOURNAL OF CLINICAL ONCOLOGY
    38. Fossa, A; Santoro, A; Hiddemann, W; Truemper, L; Niederle, N; Buksmaui, S; Bonadonna, G; Seeber, S; Nowrousian, MR
      Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

      JOURNAL OF CLINICAL ONCOLOGY
    39. Borquez, D; Seeber, S
      Strategies in the treatment of metastatic breast cancer

      ONKOLOGIE
    40. Fossa, A; Brandhorst, D; Myklebust, JH; Seeber, S; Nowrousian, MR
      Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma

      EXPERIMENTAL HEMATOLOGY
    41. Harstrick, A; Klaassen, U; Eberhardt, W; Seeber, S
      Role of chemotherapy against micrometastatic cancer

      CANCER AND METASTASIS REVIEWS
    42. Kloke, O; Klaassen, U; Oberhoff, C; Hartwich, G; Szanto, J; Wolf, E; Heckmann, M; Huhn, R; Stephan, L; Schnepper, U; Donsbach, GM; Bechtel, C; Rudolph, R; Berke, A; Borquez, D; Hawig, I; Hirche, H; Schindler, AE; Seeber, S; Becher, R
      Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial

      BREAST CANCER RESEARCH AND TREATMENT
    43. Flasshove, M; Frings, W; Schroder, JK; Moritz, T; Schutte, J; Seeber, S
      Transfer of the cytidine deaminase cDNA into hematopoietic cells

      LEUKEMIA RESEARCH
    44. Stuschke, M; Stahl, M; Wilke, H; Walz, MK; Oldenburg, AR; Stuben, G; Jahnke, K; Seeber, S; Sack, H
      Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the cervical oesophagus

      ONCOLOGY
    45. Sarbia, M; Stahl, M; Fink, U; Heep, H; Dutkowski, P; Willers, R; Seeber, S; Gabbert, HE
      Prognostic significance of cyclin D1 in esophageal squamous cell carcinomapatients treated with surgery alone or combined therapy modalities

      INTERNATIONAL JOURNAL OF CANCER
    46. Vanhoefer, U; Muller, MR; Hilger, RA; Lindtner, B; Klaassen, U; Schleucher, N; Rustum, YM; Seeber, S; Harstrick, A
      Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

      BRITISH JOURNAL OF CANCER
    47. Eberhardt, W; Stamatis, G; Stuschke, M; Wilke, H; Muller, MR; Kolks, S; Flasshove, M; Schutte, J; Stahl, M; Schlenger, L; Budach, V; Greschuchna, D; Stuben, G; Teschler, H; Sack, H; Seeber, S
      Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial

      BRITISH JOURNAL OF CANCER
    48. Elmaagacli, AH; Beelen, DW; Opalka, B; Seeber, S; Schaefer, UW
      The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow

      BLOOD
    49. Julicher, K; Marquitan, G; Werner, N; Bardenheuer, W; Vieten, L; Brocker, F; Topal, H; Seeber, S; Opalka, B; Schutte, J
      Novel tumor suppressor locus in human chromosome region 3p14.2

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    50. SARBIA M; STABL M; ZURHAUSEN A; ZIMMERMANN K; WANG LH; FINK U; HEEP H; DUTKOWSKI P; WILLERS R; MULLER W; SEEBER S; GABBERT HE
      EXPRESSION OF P21(WAF1) PREDICTS OUTCOME OF ESOPHAGEAL CANCER-PATIENTS TREATED BY SURGERY ALONE OR BY COMBINED THERAPY MODALITIES

      Clinical cancer research
    51. KORFEL A; SCHEULEN ME; SCHMOLL HJ; GRUNDEL O; HARSTRICK A; KNOCHE M; FELS LM; SKORZEC M; BACH F; BAUMGART J; SASS G; SEEBER S; THIEL E; BERDEL WE
      PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF TITANOCENE DICHLORIDE IN ADULTS WITH ADVANCED SOLID TUMORS

      Clinical cancer research
    52. Sarbia, M; Stahl, M; Fink, U; Willers, R; Seeber, S; Gabbert, HE
      Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities

      CLINICAL CANCER RESEARCH
    53. STRUMBERG D; ERHARD J; HARSTRICK A; KLAASSEN U; MULLER C; EBERHARDT W; WILKE H; SEEBER S
      PHASE-I STUDY OF A WEEKLY 1 H INFUSION OF PACLITAXEL IN PATIENTS WITHUNRESECTABLE HEPATOCELLULAR-CARCINOMA

      European journal of cancer
    54. HARSTRICK A; GONZALES A; SCHLEUCHER N; VANHOEFER U; LU K; FORMENTO JL; MILANO G; WILKE H; SEEBER S; RUSTUM Y
      COMPARISON BETWEEN SHORT OR LONG EXPOSURE TO 5-FLUOROURACIL IN HUMAN GASTRIC AND COLON-CANCER CELL-LINES - BIOCHEMICAL-MECHANISM OF RESISTANCE

      Anti-cancer drugs
    55. HARTMANN JT; HARSTRICK A; DAIKELER T; KOLLMANNSBERGER C; MULLER C; SEEBER S; KANZ L; BOKEMEYER C
      PHASE-II STUDY OF CONTINUOUS 120 H INFUSION OF MITOMYCIN-C AS SALVAGECHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER

      Anti-cancer drugs
    56. KLAASSEN U; HARSTRICK A; STRUMBERG D; WILKE H; SEEBER S
      PACLITAXEL PLUS IFOSFAMIDE IN ADVANCED OVARIAN-CANCER - RESULTS OF A PHASE-I STUDY

      Anti-cancer drugs
    57. KLAASSEN U; WILKE H; WEYHOFEN R; HARSTRICK A; EBERHARDT W; MULLER C; KORN M; HANSKE M; DIERGARTEN K; SEEBER S
      PHASE-II STUDY WITH CISPLATIN AND PACLITAXEL IN COMBINATION WITH WEEKLY HIGH-DOSE 24 H INFUSIONAL 5-FLUOROURACIL LEUCOVORIN FOR FIRST-LINE TREATMENT OF METASTATIC BREAST-CANCER/

      Anti-cancer drugs
    58. KLAASSEN U; WILKE H; HARSTRICK A; PARI CP; STRUMBERG D; NEWMANN K; EBERHARDT W; ACHTERRATH W; LENAZ L; SEEBER S
      PACLITAXEL IN COMBINATION WITH WEEKLY 24-HOUR INFUSIONAL 5-FLUOROURACIL PLUS LEUCOVORIN IN THE 2ND-LINE TREATMENT OF METASTATIC BREAST-CANCER - RESULTS OF A PHASE-II STUDY

      Annals of oncology
    59. KASIMIRBAUER S; KLAASSEN U; KADING J; SEEBER S
      DETECTION OF ISOLATED BREAST-CARCINOMA CELLS IN BONE-MARROW AND STEM-CELL GRAFTS BY IMMUNOMAGNETIC SEPARATION AND IMMUNOCYTOCHEMISTRY

      Annals of oncology
    60. BORQUEZ D; RAAB G; HARSTRICK A; WILKE HJ; ACHTERRATH W; EIERMANN W; SEEBER S
      PHASE-I STUDY OF DOCETAXEL (D) IN COMBINATION WITH EPIRUBICIN (E) AS FIRST LINE CHEMOTHERAPY IN METASTATIC BREAST-CANCER

      Annals of oncology
    61. HARSTRICK A; MAYER S; HILGER R; MULLER C; DOHMEN D; KLOPPEL R; VANHOEFER U; SCHEULEN ME; WILKE H; SEEBER S
      COMBINATION THERAPY WITH INFUSIONAL 5-FU AND TOMUDEX FOR PATIENTS (PTS) WITH ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY

      Annals of oncology
    62. WILKE H; VANHOEFER U; HARSTRICK A; ACHTERRATH W; PREUSSER P; CLEMENS MR; THIEL E; FLASSHOVE M; FINK U; SEEBER S
      PHASE-II STUDY OF DOCETAXEL (D) AS SALVAGE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC-CANCER

      Annals of oncology
    63. NOWROUSIAN MR; WELT A; FOSSA A; KASPER C; SCHRODER J; KUHLMANN S; SCHUTTE J; KLOKE O; STUSCHKE M; SCHULEHEIN K; METZ KA; LEDER LD; SACK H; SEEBER S
      RESPONSE-ADAPTED SEQUENTIAL COMBINATION CHEMOTHERAPY (CEBOPP VIML) FOLLOWED BY RADIOTHERAPY FOR BULKY AND ADVANCED-STAGE HODGKINS-DISEASE/

      Annals of oncology
    64. VANHOEFER U; HAPKE G; HARSTRICK A; ACHTERRATH W; RUSTUM YM; SEEBER S
      SCHEDULE-DEPENDENT ANTITUMOR EFFICACY OF IRINOTECAN (CPT-11) AND 5-FLUOROURACIL (5-FU) IN NUDE-MICE BEARING COLON-TUMOR XENOGRAFTS THAT ARERESISTANT TO 5-FU

      Annals of oncology
    65. MAYER S; HARSTRICK A; MULLER C; DOHMEN D; HILGER R; SCHEULEN ME; WILKE H; SEEBER S
      PHASE-I STUDY OF TOMUDEX COMBINED WITH PROTRACTED INFUSION OF 5-FU INPATIENTS (PTS) WITH METASTATIC COLORECTAL-CANCER

      Annals of oncology
    66. WELT A; FOSSA A; BLATTER J; BUKSMAUI S; SEEBER S; NOWROUSIAN MR
      GEMCITABINE AS SINGLE-AGENT IN THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN-LYMPHOMA (NHL)

      Annals of oncology
    67. Muller, MR; Thomale, J; Rajewsky, MF; Seeber, S
      Drug resistance and DNA repair in leukaemia

      CYTOTECHNOLOGY
    68. KLAASSEN U; WILKE H; HARSTRICK A; SEEBER S
      FLUOROURACIL-BASED COMBINATIONS IN THE TREATMENT OF METASTATIC BREAST-CANCER

      Oncology
    69. FOSSA A; MUER M; KASPER C; WELT A; SEEBER S; NOWROUSIAN MR
      BOLUS VINCRISTINE AND EPIRUBICIN WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE (VECD) AS INDUCTION AND SALVAGE TREATMENT IN MULTIPLE-MYELOMA

      Leukemia
    70. EBERHARDT W; WILKE H; STAMATIS G; STUSCHKE M; HARSTRICK A; MENKER H; KRAUSE B; MUELLER MR; STAHL M; FLASSHOVE M; BUDACH V; GRESCHUCHNA D; KONIETZKO N; SACK H; SEEBER S
      PREOPERATIVE CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIATION THERAPY BASED ON HYPERFRACTIONATED ACCELERATED RADIOTHERAPY AND DEFINITIVE SURGERY IN LOCALLY ADVANCED NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF A PHASE-II TRIAL

      Journal of clinical oncology
    71. KASIMIRBAUER S; OTTINGER HD; BELKA C; STELLBERG W; HALFMEYER K; GEWALTIG I; HARSTRICK A; GROSSEWILDE H; SEEBER S; SCHEULEN ME
      ANALYSIS OF THE RELATIONSHIP OF P53 STATUS AND RESISTANCE TO CHEMOTHERAPY IN CANCER CELL-LINES AS EVALUATED BY LUMINOMETRIC IMMUNOASSAY (LIA)

      Tumordiagnostik & Therapie
    72. HARSTRICK A; VANHOEFER U; SEEBER S
      NEW DRUGS IN COLORECTAL-CANCER - A REVIEW OF ANTITUMOR-ACTIVITY AND CROSS-RESISTANCE PATTERNS OF TOPOISOMERASE-I INHIBITORS, THYMIDYLATE SYNTHETASE INHIBITORS, AND OXALIPLATIN

      Onkologie
    73. VANHOEFER U; HARSTRICK A; SEEBER S
      EFFECT OF 4-HYDROPEROXYIFOSFAMIDE ON THE CELLULAR GLUTATHIONE PATHWAY

      Onkologie
    74. HILGER RA; HARSTRICK A; EBERHARDT W; OBERHOFF C; SKORZEC M; BAUMGART J; SEEBER S; SCHEULEN ME
      CLINICAL PHARMACOKINETICS OF INTRAVENOUS TREOSULFAN IN PATIENTS WITH ADVANCED SOLID TUMORS

      Cancer chemotherapy and pharmacology
    75. KIRCH HC; SCHRODER J; HOPPE H; ESCHE H; SEEBER S; SCHUTTE J
      RECOMBINANT GENE-PRODUCTS OF 2 NATURAL VARIANTS OF THE HUMAN CYTIDINEDEAMINASE GENE CONFER DIFFERENT DEAMINATION RATES OF CYTARABINE IN-VITRO

      Experimental hematology
    76. KASIMIRBAUER S; OTTINGER H; MEUSERS P; BEELEN DW; BRITTINGER G; SEEBER S; SCHEULEN ME
      IN ACUTE MYELOID-LEUKEMIA, COEXPRESSION OF AT LEAST 2 PROTEINS, INCLUDING P-GLYCOPROTEIN, THE MULTIDRUG RESISTANCE-RELATED PROTEIN, BCL-2, MUTANT P53, AND HEAT-SHOCK-PROTEIN-27, IS PREDICTIVE OF THE RESPONSE TO INDUCTION CHEMOTHERAPY

      Experimental hematology
    77. CASPER J; FREUND M; HARSTRICK A; SCHEULEN ME; BORNHAUSER M; EHNINGER G; JOSTEN KM; BAUMGART J; SEEBER S
      CLINICAL-PHASE-I TRIAL OF HIGH-DOSE TREOSULFAN WITH AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL REINFUSION (PBSCT)

      Bone marrow transplantation
    78. Hoffken, K; Merkle, K; Schonfelder, M; Anger, G; Brandtner, M; Ridwelski, K; Seeber, S
      Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    79. ALAMIN A; LENNARTZ K; RUNDE V; SEEBER S; OPALKA B; KLOKE O
      FREQUENCY OF CLONAL B-LYMPHOCYTES IN CHRONIC MYELOGENOUS LEUKEMIA EVALUATED BY FLUORESCENCE IN-SITU HYBRIDIZATION

      Cancer genetics and cytogenetics
    80. SCHRODER JK; SEIDELMANN M; KIRCH HC; SEEBER S; SCHUTTE J
      ASSESSMENT OF RESISTANCE INDUCTION TO CYTOSINE-ARABINOSIDE FOLLOWING TRANSFER AND OVEREXPRESSION OF THE DEOXYCYTIDYLATE DEAMINASE GENE IN-VITRO

      Leukemia research
    81. KASIMIRBAUER S; OTTINGER H; WUTTKE M; STELLBERG W; GROSSEWILDE H; SEEBER S; SCHEULEN ME
      CHRONIC MYELOGENOUS LEUKEMIA - EFFECT OF INTERFERON-ALPHA TREATMENT ON PHAGOCYTIC-ACTIVITY AND CAPACITY OF CIRCULATING NEUTROPHILS

      Leukemia research
    82. GATZEMEIER U; MANEGOLD C; EBERHARD W; WILKE HJ; CHOMY F; CHOMY P; KHAYAT D; BLATTER J; SEEBER S; DRINGS P
      IFOSFAMIDE AND GEMCITABINE - A PHASE-II TRIAL IN ADVANCED INOPERABLE NONSMALL CELL LUNG-CANCER

      Seminars in oncology
    83. WELT A; ANHUF J; KRAWCZYK C; FOSSA A; STUSCHKE M; KLOKE O; SCHUTTE J; WESTERHAUSEN M; SACK H; SEEBER S; NOWROUSIAN MR
      INITIAL HIGH-DOSE SEQUENTIAL CHEMOTHERAPY IN THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH RISK-FACTORS

      British Journal of Haematology
    84. KUHLMANN S; FOSSA A; WRZECIONO T; KASPER C; WELT A; SEEBER S; NOWROUSIAN MR
      HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND AUTOLOGOUS PERIPHERAL STEM-CELLTRANSPLANTATION IN PATIENTS WITH PREVIOUSLY TREATED OR UNTREATED MULTIPLE-MYELOMA

      British Journal of Haematology
    85. Schroder, JK; Kirch, C; Seeber, S; Schutte, J
      Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    86. MULLER MR; BUSCHFORT C; THOMALE J; LENSING C; RAJEWSKY MF; SEEBER S
      DNA-REPAIR AND CELLULAR-RESISTANCE TO ALKYLATING-AGENTS IN CHRONIC LYMPHOCYTIC-LEUKEMIA

      Clinical cancer research
    87. SIEBERT R; FOSSA A; KAISER W; WELT A; FERENCIK S; SEEBER S; NOWROUSIAN MR
      RECURRENCE OF HODGKINS-DISEASE AFTER 10 OR MORE YEARS - LATE RELAPSE OR DE-NOVO MALIGNANCY DUE TO HLA-DPB1-ASTERISK-0301-LINKED SUSCEPTIBILITY

      Leukemia & lymphoma
    88. VANHOEFER U; VOIGT W; HILGER RA; YIN MB; HARSTRICK A; SEEBER S; RUSTUM YM
      CELLULAR DETERMINANTS OF RESISTANCE TO INDOLOCARBAZOLE ANALOG LO[2,3-ALPHA]PYRROLO[3,4-C]CARBAZOLE-5,7(6H)-DIONE (NB-506), A NOVEL POTENT TOPOISOMERASE-I INHIBITOR, IN MULTIDRUG-RESISTANT HUMAN TUMOR-CELLS

      Oncology research
    89. HARSTRICK A; FOSSA A; ZASADZINSKI E; MAYER S; BOJKO P; FLASSHOVE M; NOWROUSIAN MR; SCHUTTE J; SEEBER S
      INTENSIFIED SALVAGE THERAPY FOR GERM-CELL CANCER USING SEQUENTIAL CYCLES OF HIGH-DOSE CARBOPLATIN ETOPOSIDELCYDO-PHOSPHAMIDE (CEC)/

      European journal of cancer
    90. HARSTRICK A; VANHOEFER U; HEIDEMANN A; DRUYEN H; WILKE H; SEEBER S
      DRUG-INTERACTIONS OF 5-FLUOROURACIL WITH EITHER CISPLATIN OR LOBAPLATIN - A NEW, CLINICALLY ACTIVE PLATINUM ANALOG IN ESTABLISHED HUMAN CANCER CELL-LINES

      Anti-cancer drugs
    91. STRUMBERG D; HARSTRICK A; KLAASSEN U; MULLER C; EBERHARDT W; KERN MW; WILKE H; SEEBER S
      PHASE-II TRIAL OF CONTINUOUS ORAL TROFOSFAMIDE IN PATIENTS WITH ADVANCED COLORECTAL-CANCER REFRACTORY TO 5-FLUOROURACIL

      Anti-cancer drugs
    92. HARSTRICK A; KOHNE CH; HIDDEMANN W; PREUSSER P; STRUMBERG D; BERNS T; SEEBER S; WILKE H; SCHMOLL HJ
      MODULATION OF 5-FLUOROURACIL WITH METHOTREXATE AND LOW-DOSE N-(PHOSPHONACETYL)-L-ASPARTATE (PALA) IS INACTIVE IN ADVANCED PANCREATIC-CARCINOMA

      Annals of oncology
    93. VANHOEFER U; CAO S; HARSTRICK A; SEEBER S; RUSTUM YM
      COMPARATIVE ANTITUMOR EFFICACY OF DOCETAXEL AND PACLITAXEL IN NUDE-MICE BEARING HUMAN TUMOR XENOGRAFTS THAT OVEREXPRESS THE MULTIDRUG-RESISTANCE PROTEIN (MRP)

      Annals of oncology
    94. KASPER C; TERHAAR A; FOSSA A; WELT A; SEEBER S; NOWROUSIAN MR
      RECOMBINANT-HUMAN-ERYTHROPOIETIN IN THE TREATMENT OF CANCER-RELATED ANEMIA

      European journal of haematology
    95. RUSTUM YM; HARSTRICK A; CAO SS; VANHOEFER U; YIN MB; WILKE H; SEEBER S
      THYMIDYLATE SYNTHASE INHIBITORS IN CANCER-THERAPY - DIRECT AND INDIRECT INHIBITORS

      Journal of clinical oncology
    96. TRARBACH T; SCHEULEN ME; SCHRODER J; STUSCHKE M; SEEBER S; SCHUTTE J
      PHASE-II TRIAL OF FIRST-LINE HIGH-DOSE IFOSFAMIDE IN ADVANCED ADULT SOFT-TISSUE SARCOMA

      Tumordiagnostik & Therapie
    97. SCHEULEN ME; KLANIG H; WIEFELSPUTZ JK; KAMPER P; WAGNER B; KONIETZKO N; SEEBER S
      PRETHERAPEUTIC EVALUATION OF CYTOKERATIN FRAGMENT-19 (CYFRA-21-1) IN 240 PATIENTS WITH LUNG-CANCER IN COMPARISON TO CARCINOEMBRYONIC ANTIGEN (CEA), NEURON-SPECIFIC ENOLASE (NSE), SQUAMOUS-CELL CARCINOMA ANTIGEN (SCC-AG), TISSUE POLYPEPTIDE ANTIGEN (TPA) AND TISSUE POLYPEPTIDE SPECIFIC ANTIGEN (TPS)

      Tumordiagnostik & Therapie
    98. SCHEULEN ME; EBERHARDT W; KLANIG H; KRAUSE B; WIEFELSPUTZ JK; KAMPER P; SEEBER S
      CYFRA-21-1 IN THE FOLLOW-UP OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL-CELL LUNG-CANCER DURING AND AFTER NEOADJUVANT CHEMORADIOTHERAPY ANDSURGERY

      Tumordiagnostik & Therapie
    99. LUX A; BARDENHEUER W; MICHAEL D; BROCKER F; JULICHER K; VIETEN L; MICHAELIS S; SEEBER S; OPALKA B; SCHUTTE J
      IDENTIFICATION OF NOVEL EXPRESSED SEQUENCE TAGS WITHIN THE FHIT GENE LOCUS IN HUMAN-CHROMOSOME REGION 3P14.2

      Human genetics
    100. JANSEN M; STEINIGER H; BARDENHEUER W; FLASSHOVE M; SEEBER S; MORITZ T
      REDUCTION OF ALKYLATING AGENT INDUCED TOXICITY BY O'-METHYLGUANIN-METHYLTRANSFERASE (MGMT) OVEREXPRESSION IN HEMATOPOEITIC CELLS

      Experimental hematology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/11/20 alle ore 03:14:50